Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
antiemetic |
| gptkbp:approvalYear |
1997
|
| gptkbp:ATCCode |
A04AA04
|
| gptkbp:brand |
Anzemet
|
| gptkbp:CASNumber |
115956-12-6
|
| gptkbp:contraindication |
QT prolongation
|
| gptkbp:developedBy |
gptkb:Sanofi-Aventis
|
| gptkbp:drugClass |
5-HT3 receptor antagonist
|
| gptkbp:eliminationHalfLife |
7-9 hours
|
| gptkbp:hasMolecularFormula |
C19H20N2O3
|
| https://www.w3.org/2000/01/rdf-schema#label |
dolasetron
|
| gptkbp:indication |
chemotherapy-induced nausea and vomiting
postoperative nausea and vomiting |
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
blocks serotonin 5-HT3 receptors
|
| gptkbp:metabolism |
hydrodolasetron
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:routeOfAdministration |
oral
intravenous |
| gptkbp:sideEffect |
diarrhea
dizziness fatigue headache |
| gptkbp:UNII |
VL63VZ1Z4D
|
| gptkbp:usedFor |
prevention of nausea and vomiting
treatment of nausea and vomiting |
| gptkbp:bfsParent |
gptkb:5-HT3_receptor
gptkb:serotonin_5-HT3_receptor |
| gptkbp:bfsLayer |
7
|